193 related articles for article (PubMed ID: 29877131)
21. Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female.
Oliver JD; Boesch RP; Mack KJ
Headache; 2018 Sep; 58(8):1259-1261. PubMed ID: 30033516
[No Abstract] [Full Text] [Related]
22. Onabotulinumtoxin [corrected] A (Botox).
Tepper D
Headache; 2014 Apr; 54(4):787-8. PubMed ID: 24697235
[No Abstract] [Full Text] [Related]
23. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
24. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
[TBL] [Abstract][Full Text] [Related]
25. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
de Tommaso M; Brighina F; Delussi M
Eur Neurol; 2019; 81(1-2):37-46. PubMed ID: 31013496
[TBL] [Abstract][Full Text] [Related]
26. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
Lyseng-Williamson KA; Frampton JE
CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
[TBL] [Abstract][Full Text] [Related]
27. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
28. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
[TBL] [Abstract][Full Text] [Related]
29. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
Maasumi K; Thompson NR; Kriegler JS; Tepper SJ
Headache; 2015 Oct; 55(9):1218-24. PubMed ID: 26381856
[TBL] [Abstract][Full Text] [Related]
30. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
Russo M; Manzoni GC; Taga A; Genovese A; Veronesi L; Pasquarella C; Sansebastiano GE; Torelli P
Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
[TBL] [Abstract][Full Text] [Related]
31. Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.
Ceccardi G; Schiano di Cola F; Caratozzolo S; Di Pasquale M; Bolchini M; Padovani A; Rao R
Toxins (Basel); 2023 Nov; 15(12):. PubMed ID: 38133181
[TBL] [Abstract][Full Text] [Related]
32. Wearing Off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients.
Quintas S; García-Azorín D; Heredia P; Talavera B; Gago-Veiga AB; Guerrero ÁL
Pain Med; 2019 Sep; 20(9):1815-1821. PubMed ID: 30657951
[TBL] [Abstract][Full Text] [Related]
33. Botox for chronic migraine.
Drug Ther Bull; 2011 Feb; 49(2):22-4; quiz iii-iv. PubMed ID: 21304165
[TBL] [Abstract][Full Text] [Related]
34. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
[TBL] [Abstract][Full Text] [Related]
35. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
Algahtani H; Shirah B; Sukkar G; Bukhari H; Meftah I; Alhazmi A; Alshareef A; Algethami A; Alshanqiti A; Andeejani M
Acta Neurol Belg; 2021 Dec; 121(6):1783-1787. PubMed ID: 33058053
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.
Lin KH; Chen SP; Fuh JL; Wang YF; Wang SJ
J Chin Med Assoc; 2014 Jan; 77(1):10-5. PubMed ID: 24269600
[TBL] [Abstract][Full Text] [Related]
38. [Clinical experience of treatment with onabotulinumtoxin A in patients with refractory migraine].
Palma JA; Irimia P; Fernandez-Torron R; Ortega-Cubero S; Riverol M; Luquin MR; Martinez-Vila E
Rev Neurol; 2012 Jun; 54(12):705-11. PubMed ID: 22673946
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
[TBL] [Abstract][Full Text] [Related]
40. OnabotulinumtoxinA in pediatric chronic daily headache.
Kabbouche M; O'Brien H; Hershey AD
Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
